An observational study in Simvastatin Adverse Reaction, Pharmacogenomics and Accurate Medication, sponsored by Cui Yimin. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-22.
Sponsored by Cui Yimin · Observational
Adverse reactions of simvastatin are mostly slight and transient, however, the incidence of simvastatin-induced hepatic impairment and myopathy are obviously higher in Chinese population than other racial groups. There is still lack of research data in Chinese. In this study, we will investigate whether there are specific genotypes which may predict the incidence of simvastatin-induced hepatic impairment and myopathy in Chinese so as to provide a basis for developing guidelines on precise medication in simvastatin therapy apply to Chinese population.
Chinese Patients:In accordance with anti-hyperlipemia indications of simvastatin
Exclusion Criteria:
Through next generation sequencing, distinguish wild genotype of simvastatin
Genetic: detection of genotype
Through next generation sequencing, distinguish mutant genotype of simvastatin
Genetic: detection of genotype
detection of genotype by next generation sequencing
Incidence of hepatic impairment
Time frame: At 2 years
Incidence of myopathy
Time frame: At 2 years
Genotype detected by next generation sequencing
Collect blood specimen before simvastatin administration, then detect genotype of simvastatin by next generation sequencing.
Time frame: pre-dose of simvastatin(Baseline)
This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Drug-Related Side Effects and Adverse Reactions→
Cui Yimin